Investigational biologic

ACE-083

An investigational locally acting muscle-growth agent that increased treated-muscle volume in clinical trials but did not consistently improve strength or function.

Evidence confidence

Human
2/5
Some human clinical evidence
1 citation
Animal
Not yet assessed
Trust Engine review pending.
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
2/5
Partially characterised safety
1 citation

Claimed uses

Mechanisms

Safety notes

Injection-site reactions were common. Increasing muscle volume without reliable functional improvement limits clinical relevance. Safety outside controlled trials and product quality in unregulated markets are uncertain.

Regulation
  • Not approved for routine clinical use or bodybuilding. Development was discontinued after phase 2 programmes failed to show consistent functional benefit.

References

  1. Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy · 2022
Last reviewed
11 July 2026
Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.